Loading...
Market
How will Evotec's stock perform compared to the DAX index by April 30, 2025?
2
Resolution / Starting Odds
Outperforms DAX by more than 10% • 25%
Outperforms DAX by up to 10% • 25%
Performs similar to DAX • 25%
Underperforms DAX • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Evotec Shares Surge 13.3% as Triton Considers Takeover with Near 10% Stake
Nov 11, 2024, 11:00 AM
Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed that private equity firm Triton had built an over 9% stake in the German drug development company. Triton Partners is considering a takeover bid for Evotec, following its emergence as one of the drug developer’s largest shareholders. Triton has become the biggest shareholder with a near 10% stake.
View original story
Similar markets
Increase by 0-5% • 25%
Increase by 5-10% • 25%
Increase by 10-15% • 25%
Increase by more than 15% • 25%
DAX Index outperforms all • 25%
DAX Index outperforms most but not all • 25%
DAX Index performs average • 25%
DAX Index underperforms • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Increased by more than 10% • 25%
Increased by 0-10% • 25%
Decreased by 0-10% • 25%
Decreased by more than 10% • 25%
Decrease by 5% or more • 25%
Change between -5% and 5% • 25%
Increase between 5% and 10% • 25%
Increase by 10% or more • 25%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Yes • 50%
No • 50%
Successful acquisition at €11 per share • 25%
Acquisition at a different price • 25%
Acquisition fails • 25%
Acquisition postponed • 25%
Roche • 25%
Novartis • 25%
Sanofi • 25%
No counteroffer • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change or decrease • 25%
Decrease by more than 10% • 25%